Cargando…

High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors

Proteasome inhibitors (PIs) are approved backbone treatments in multiple myeloma. More recently, inhibition of proteasome activity with the PI bortezomib has been clinically evaluated as a novel treatment strategy in pediatric acute lymphoblastic leukemia (ALL). However, we lack a marker that could...

Descripción completa

Detalles Bibliográficos
Autores principales:	Besse, Lenka, Besse, Andrej, Kraus, Marianne, Maurits, Elmer, Overkleeft, Herman S., Bornhauser, Beat, Bourquin, Jean-Pierre, Driessen, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616377/ https://www.ncbi.nlm.nih.gov/pubmed/34831075 http://dx.doi.org/10.3390/cells10112853

Ejemplares similares

Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors
por: Besse, Andrej, et al.
Publicado: (2022)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
por: Schwestermann, Jonas, et al.
Publicado: (2022)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Besse, Lenka, et al.
Publicado: (2023)

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells
por: Kraus, Johannes, et al.
Publicado: (2015)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
por: Soriano, G P, et al.
Publicado: (2016)

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
por: Besse, L, et al.
Publicado: (2017)

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
por: Zhou, Xiang, et al.
Publicado: (2023)

IRS1 deficiency protects β-cells against ER stress-induced apoptosis by modulating sXBP-1 stability and protein translation
por: Takatani, Tomozumi, et al.
Publicado: (2016)

Corrigendum: IRS1 deficiency protects β-cells against ER stress-induced apoptosis by modulating sXBP-1 stability and protein translation
por: Takatani, Tomozumi, et al.
Publicado: (2016)

Poly (ADP-ribose) polymerases 16 triggers pathological cardiac hypertrophy via activating IRE1α–sXBP1–GATA4 pathway
por: Su, Haibi, et al.
Publicado: (2023)

Denervation-Induced Activation of the Standard Proteasome and Immunoproteasome
por: Liu, Haiming M., et al.
Publicado: (2016)

Structure‐Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits
por: Maurits, Elmer, et al.
Publicado: (2020)

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
por: Besse, A, et al.
Publicado: (2018)

Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome
por: Diez-Rivero, Carmen M, et al.
Publicado: (2010)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Immunoproteasome Inhibitor–Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin upon Low-Dose Photon Irradiation
por: Maurits, Elmer, et al.
Publicado: (2020)

Evaluation of Proteasome and Immunoproteasome Levels in Plasma and Peritoneal Fluid in Patients with Endometriosis
por: Wróbel, Monika, et al.
Publicado: (2023)

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
por: Zhou, X., et al.
Publicado: (2023)

Regulation of Immunoproteasome Function in the Lung
por: Keller, Ilona E., et al.
Publicado: (2015)

Methods for 20S Immunoproteasome and 20S Constitutive Proteasome Determination Based on SPRI Biosensors
por: Anna, Sankiewicz, et al.
Publicado: (2017)

Gastric cancer cell types display distinct proteasome/immunoproteasome patterns associated with migration and resistance to proteasome inhibitors
por: Monittola, Francesca, et al.
Publicado: (2023)

The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies
por: Krupkova, Olga, et al.
Publicado: (2018)

Immunoproteasome dysfunction augments alternative polarization of alveolar macrophages
por: Chen, S, et al.
Publicado: (2016)

Manifolds all of whose geodesics are closed
por: Besse, Arthur L
Publicado: (1978)

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
por: Seyfried, Felix, et al.
Publicado: (2019)

Pcleavage: an SVM based method for prediction of constitutive proteasome and immunoproteasome cleavage sites in antigenic sequences
por: Bhasin, Manoj, et al.
Publicado: (2005)

Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits
por: Xin, Bo-Tao, et al.
Publicado: (2019)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Hypoxia-induced shift in the phenotype of proteasome from 26S toward immunoproteasome triggers loss of immunoprivilege of mesenchymal stem cells
por: Abu-El-Rub, Ejlal, et al.
Publicado: (2020)

Dysfunctional immunoproteasomes in autoinflammatory diseases
por: Arimochi, Hideki, et al.
Publicado: (2016)

On the Role of the Immunoproteasome in Protein Homeostasis
por: Basler, Michael, et al.
Publicado: (2021)

The Function of Immunoproteasomes—An Immunologists’ Perspective
por: van den Eshof, Bart L., et al.
Publicado: (2021)

Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
por: Besse, Lenka, et al.
Publicado: (2021)

Immunoproteasome functions explained by divergence in cleavage specificity and regulation
por: Winter, Michael B, et al.
Publicado: (2017)

ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation
por: Zhang, Dan, et al.
Publicado: (2020)

Immunoproteasome Function in Normal and Malignant Hematopoiesis
por: Tubío-Santamaría, Nuria, et al.
Publicado: (2021)

Immunoproteasome inhibition attenuates experimental psoriasis
por: del Rio Oliva, Marta, et al.
Publicado: (2022)

A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes
por: Burov, Alexander, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dk9nbdetc02n857uer4beg1dhh